Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)ASX AI Signals has generated 3 signal for MVP during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest MVP Signals | |
| 27/04/2026 | BUY |
| 26/04/2026 | BUY |
| 25/04/2026 | BUY |
MVP Share Price | |
| Current Price | $0.415 |
| 52 Week High | $0.760 |
| 52 Week Low: | $0.370 |
| Trading at (% of 52 Week High) | 54.61% |
Medical Developments International Limited (ASX: MVP) is an Australian company that develops, manufactures, and markets medical products primarily for pain and respiratory relief. The company is known for its signature product, Penthrox, an inhaled analgesic used in emergency and pre-hospital care settings. Medical Developments International operates globally, supplying healthcare providers and emergency services.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The BUY signal for MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP) is supported by positive momentum and potential growth in the medical devices sector. However, the relatively low stock price and market volatility introduce moderate risk, warranting a cautious approach.
The ASX200 showed resilience today, closing in the green as investors reacted positively to encouraging inflation data that could lead to an interest rate cut in August. In this environment of sectoral strength and selective challenges, identifying stocks trading below their intrinsic value can offe Multiple insiders secured a larger position in Medical Developments International Limited (ASX:MVP) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism about the company's prospects.
While we would never suggest that investors should base their Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't succeed. To wit, the Medical Developments International Limited (ASX:MVP) share price managed to fall 53% over five long years. That's an unpleasant experience for long term holders. We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Having said that, unprofitable c Market forces rained on the parade of Medical Developments International Limited (ASX:MVP) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially moreLatest MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED(MVP) News
ASX Stocks Estimated To Be Trading Below Intrinsic Value In July 2025
Bullish Medical Developments International Limited (ASX:MVP) insiders filled their treasuries with AU$1.7m worth of stock over last year
Medical Developments International (ASX:MVP) shareholders have endured a 52% loss from investing in the stock five years ago
We're Hopeful That Medical Developments International (ASX:MVP) Will Use Its Cash Wisely
The Medical Developments International Limited (ASX:MVP) Analysts Have Been Trimming Their Sales Forecasts
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial